Search research articles
Contact Us
Filters
Showing results (31-40 of 55) with videos related to
Page
of 6
Sort By:
Hemasphere
|
November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure
Mwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Journal of Hematology & Oncology
|
March 18, 2025
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
Elvira Umyarova, Charles Pei, William Pellegrino, et al.
Haematologica
|
April 27, 2023
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes
Charlotte B Wagner, Ken Boucher, Adrienne Nedved, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience
Muhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
American Journal of Hematology
|
July 29, 2021
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era
Reem Karmali, Jeffrey M Switchenko, Subir Goyal, et al.
Blood Advances
|
April 12, 2024
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
Nathan Denlinger, No-Joon Song, Xiaoli Zhang, et al.
European Journal of Haematology
|
May 11, 2021
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival
Krithika Shanmugasundaram, Subir Goyal, Jeffery Switchenko, et al.
Blood Advances
|
January 17, 2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics
Pallawi Torka, Shalin K Kothari, Suchitra Sundaram, et al.
Blood Advances
|
September 13, 2021
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy
David A Bond, Jeffrey M Switchenko, Diego Villa, et al.
Blood Advances
|
August 27, 2024
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Narendranath Epperla, Adam S Zayac, Daniel J Landsburg, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 55) with videos related to
Sort By:
Page
of 6
Hemasphere
|
November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure
Mwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Journal of Hematology & Oncology
|
March 18, 2025
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
Elvira Umyarova, Charles Pei, William Pellegrino, et al.
Haematologica
|
April 27, 2023
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes
Charlotte B Wagner, Ken Boucher, Adrienne Nedved, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience
Muhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
American Journal of Hematology
|
July 29, 2021
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era
Reem Karmali, Jeffrey M Switchenko, Subir Goyal, et al.
Blood Advances
|
April 12, 2024
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
Nathan Denlinger, No-Joon Song, Xiaoli Zhang, et al.
European Journal of Haematology
|
May 11, 2021
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival
Krithika Shanmugasundaram, Subir Goyal, Jeffery Switchenko, et al.
Blood Advances
|
January 17, 2020
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics
Pallawi Torka, Shalin K Kothari, Suchitra Sundaram, et al.
Blood Advances
|
September 13, 2021
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy
David A Bond, Jeffrey M Switchenko, Diego Villa, et al.
Blood Advances
|
August 27, 2024
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Narendranath Epperla, Adam S Zayac, Daniel J Landsburg, et al.
Page
of 6